151 related articles for article (PubMed ID: 20080926)
1. The influence of 5-HTT and COMT genotypes on verbal fluency in ecstasy users.
Fagundo AB; Cuyàs E; Verdejo-Garcia A; Khymenets O; Langohr K; Martín-Santos R; Farré M; de la Torre R
J Psychopharmacol; 2010 Sep; 24(9):1381-93. PubMed ID: 20080926
[TBL] [Abstract][Full Text] [Related]
2. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
de Sola Llopis S; Miguelez-Pan M; Peña-Casanova J; Poudevida S; Farré M; Pacifici R; Böhm P; Abanades S; Verdejo García A; Langohr K; Zuccaro P; de la Torre R
J Psychopharmacol; 2008 Jul; 22(5):498-510. PubMed ID: 18208910
[TBL] [Abstract][Full Text] [Related]
3. The effect of Ecstasy on memory is moderated by a functional polymorphism in the cathechol-O-methyltransferase (COMT) gene.
Schilt T; Koeter MW; de Win MM; Zinkstok JR; van Amelsvoort TA; Schmand B; den Brink Wv
Eur Neuropsychopharmacol; 2009 Feb; 19(2):116-24. PubMed ID: 19042106
[TBL] [Abstract][Full Text] [Related]
4. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users.
Fox HC; McLean A; Turner JJ; Parrott AC; Rogers R; Sahakian BJ
Psychopharmacology (Berl); 2002 Jul; 162(2):203-14. PubMed ID: 12110998
[TBL] [Abstract][Full Text] [Related]
5. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.
Reneman L; Schilt T; de Win MM; Booij J; Schmand B; van den Brink W; Bakker O
J Psychopharmacol; 2006 May; 20(3):389-99. PubMed ID: 16574713
[TBL] [Abstract][Full Text] [Related]
6. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
7. The effect of COMT Val158 Met genotype on decision-making and preliminary findings on its interaction with the 5-HTTLPR in healthy females.
van den Bos R; Homberg J; Gijsbers E; den Heijer E; Cuppen E
Neuropharmacology; 2009 Feb; 56(2):493-8. PubMed ID: 18983999
[TBL] [Abstract][Full Text] [Related]
8. Ecstasy (MDMA) exposure and neuropsychological functioning: a polydrug perspective.
Medina KL; Shear PK; Corcoran K
J Int Neuropsychol Soc; 2005 Oct; 11(6):753-65. PubMed ID: 16248911
[TBL] [Abstract][Full Text] [Related]
9. The effect of polymorphism at the serotonin transporter gene on decision-making, memory and executive function in ecstasy users and controls.
Roiser JP; Rogers RD; Cook LJ; Sahakian BJ
Psychopharmacology (Berl); 2006 Oct; 188(2):213-27. PubMed ID: 16941121
[TBL] [Abstract][Full Text] [Related]
10. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?
Morgan MJ; McFie L; Fleetwood H; Robinson JA
Psychopharmacology (Berl); 2002 Jan; 159(3):294-303. PubMed ID: 11862362
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological evidence of atypical processing underlying mental set shifting in ecstasy polydrug and polydrug users.
Roberts CA; Fairclough SH; McGlone FP; Fisk JE; Montgomery C
Exp Clin Psychopharmacol; 2013 Dec; 21(6):507-15. PubMed ID: 24080019
[TBL] [Abstract][Full Text] [Related]
12. Evidence of increased activation underlying cognitive control in ecstasy and cannabis users.
Roberts GM; Garavan H
Neuroimage; 2010 Aug; 52(2):429-35. PubMed ID: 20417713
[TBL] [Abstract][Full Text] [Related]
13. COMT val158met and 5-HTTLPR genetic polymorphisms moderate executive control in cannabis users.
Verdejo-García A; Fagundo AB; Cuenca A; Rodriguez J; Cuyás E; Langohr K; de Sola Llopis S; Civit E; Farré M; Peña-Casanova J; de la Torre R
Neuropsychopharmacology; 2013 Jul; 38(8):1598-606. PubMed ID: 23449176
[TBL] [Abstract][Full Text] [Related]
14. Evidence for executive deficits among users of MDMA (Ecstasy).
Fisk JE; Montgomery C; Murphy P; Wareing M
Br J Psychol; 2004 Nov; 95(Pt 4):457-66. PubMed ID: 15527532
[TBL] [Abstract][Full Text] [Related]
15. Selective impairment of sadness and disgust recognition in abstinent ecstasy users.
Yip JT; Lee TM
Neuropsychologia; 2006; 44(6):959-65. PubMed ID: 16293272
[TBL] [Abstract][Full Text] [Related]
16. Evidence for selective executive function deficits in ecstasy/polydrug users.
Fisk JE; Montgomery C
J Psychopharmacol; 2009 Jan; 23(1):40-50. PubMed ID: 18515461
[TBL] [Abstract][Full Text] [Related]
17. The effects of concurrent cannabis use among ecstasy users: neuroprotective or neurotoxic?
Fisk JE; Montgomery C; Wareing M; Murphy PN
Hum Psychopharmacol; 2006 Aug; 21(6):355-66. PubMed ID: 16915582
[TBL] [Abstract][Full Text] [Related]
18. Self reported sleep quality and cognitive performance in ecstasy users.
Montgomery C; Fisk JE; Wareing M; Murphy P
Hum Psychopharmacol; 2007 Dec; 22(8):537-48. PubMed ID: 17960556
[TBL] [Abstract][Full Text] [Related]
19. Visuo-spatial working memory deficits in current and former users of MDMA ('ecstasy').
Wareing M; Fisk JE; Murphy P; Montgomery C
Hum Psychopharmacol; 2005 Mar; 20(2):115-23. PubMed ID: 15641126
[TBL] [Abstract][Full Text] [Related]
20. The influence of genetic and environmental factors among MDMA users in cognitive performance.
Cuyàs E; Verdejo-García A; Fagundo AB; Khymenets O; Rodríguez J; Cuenca A; de Sola Llopis S; Langohr K; Peña-Casanova J; Torrens M; Martín-Santos R; Farré M; de la Torre R
PLoS One; 2011; 6(11):e27206. PubMed ID: 22110616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
